Purple Biotech Ltd Cash Flow-to-Debt Ratio
Purple Biotech Ltd cash flow-to-debt ratio. Purple Biotech Ltd (PPBT) has a Cash Flow-to-Debt Ratio of -0.17x as of September 2025, meaning its operating cash flow of ILA-1.07 Million could theoretically repay 0% of its total liabilities (ILA6.25 Million) in one year. See Purple Biotech Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Purple Biotech Ltd (2017–2024)
Cash flow-to-debt ratio of Purple Biotech Ltd from 2017 to 2024. Historical debt coverage capacity for Purple Biotech Ltd across 8 annual periods. Also explore Purple Biotech Ltd (PPBT) equity growth momentum to track the company's year-over-year net asset growth rate.
Purple Biotech Ltd Cash Flow-to-Debt Ratio by Year (2017–2024)
Purple Biotech Ltd cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Purple Biotech Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Purple Biotech Ltd.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.48x | ILA-14.37 Million | ILA4.13 Million | ▼ -74.8% |
| 2023 | -1.99x | ILA-19.93 Million | ILA10.01 Million | ▲ +10.5% |
| 2022 | -2.22x | ILA-16.73 Million | ILA7.52 Million | ▲ +25.7% |
| 2021 | -3.00x | ILA-15.25 Million | ILA5.09 Million | ▼ -0.3% |
| 2020 | -2.98x | ILA-12.09 Million | ILA4.05 Million | ▼ -106.4% |
| 2019 | -1.45x | ILA-5.58 Million | ILA3.86 Million | ▲ +36.6% |
| 2018 | -2.28x | ILA-8.48 Million | ILA3.72 Million | ▼ -47.7% |
| 2017 | -1.54x | ILA-8.63 Million | ILA5.59 Million | — |